Karyopharm Therapeutics: Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024
Karyopharm Therapeutics Inc. provided revenue guidance for the fourth quarter and full year 2024. For the quarter, the company expects total revenue to be approximately $30 million. For the full year, the company expects revenue to be $145 million.
Read full article »
Karyopharm is a Massachusetts-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of blood cancer.
Read more